The European Commission has taken a firm stance against what it sees as potentially misleading marketing, rejecting a health claim that creatine supplementation improves cognitive function. This move directly impacts food supplement manufacturers seeking to market cognitive benefits, while protecting consumers from what regulators deem unsubstantiated claims. Published on January 13, 2026, this decision comes from the Commission's Directorate-General for Health and Food Safety (DG SANTE) and is detailed in Annex to Commission Regulation (EU) .../..., referenced as ST 5235 2026 ADD 1.
The Commission Rejects Unproven Claims
This binding regulatory decision refuses authorization for a specific health claim under EU Regulation (EC) No 1924/2006, incorporating the European Food Safety Authority's (EFSA) scientific opinion Q-2024-00106. The document represents concrete regulatory action rather than vague policy statements, establishing a clear precedent for evaluating similar claims.
Prioritizing Scientific Rigor Over Market Claims
The policy direction clearly prioritizes consumer protection and scientific evidence over business marketing flexibility. This represents a cleavage between strict regulatory oversight of health claims versus allowing more permissive marketing of food supplements. The Commission strengthens enforcement of existing standards rather than relaxing them, favoring evidence-based regulation over industry self-regulation.
Stakeholders Face Divergent Impacts
Food supplement manufacturers face moderate negative impact as they lose a potential marketing claim and must reformulate or relabel products containing creatine. Consumers receive moderate positive protection from potentially misleading information about cognitive benefits. EU regulatory bodies (EFSA and Commission) strengthen their authority in health claim evaluation. National authorities benefit from clearer enforcement guidelines but face implementation costs.
Regulatory Process Continues
This decision represents the conclusion of a specific authorization procedure but signals ongoing strict enforcement of health claim regulations. The Commission's stance may influence future applications and could trigger industry appeals or legal challenges, while national authorities will implement the refusal in their markets.